Cantargia confirms enrollment in Phase IIa trial for CAN04 monotherapy
Category: #health  By Mateen Dalal  Date: 2019-07-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Cantargia confirms enrollment in Phase IIa trial for CAN04 monotherapy

All the 20 patients for the monotherapy arm of the trial have begun treatment with 10 mg/kg dosage level

Swedish biotech firm Cantargia has reportedly announced full recruitment of CAN04 monotherapy arm in an existing Phase IIa clinical study in cancer patients.

Sources with knowledge on the matter informed that CAN04 (nidanilimab) is an antibody from Cantargia which is being investigated in a three-armed open label Phase IIa trial CANFOUR. Under this, CAN04 is evaluated as monotherapy or in chemotherapy combinations in pancreatic cancer (PDAC) or non-small cell lung cancer (NSCLC) patients.

All the 20 patients for the monotherapy arm of the trial have begun treatment with 10 mg/kg dose. The Safety, overall, has been in line with Phase I results. Outcome of the monotherapy, including efficacy and biomarkers are expected to be ready during fourth quarter of 2019, the sources informed.

Cantargia, on the basis of fast recruitment and good safety, is planning to utilize this opportunity to add more patients for generating safety and biomarker data at higher dosage level. Enrollment for the combination arms is also ongoing parallel to the monotherapy arm.

Sources stated that tumor biopsies have been obtained from most for the patients in the study, which were taken before and after therapy. Analyzing these biopsies will provide insights into the impact of CAN04 in the tumor microenvironment. Biomarkers would also be analyzed in the serum and the outcomes of these analyses are expected together with the efficacy results from CT-sans, sources added.

For the uninitiated, Cantargia develops pharmaceuticals based on antibodies against the interleukin 1 receptor accessory protein, or IL1RAP. IL1RAP with high functions and affinity is bound by antibody CAN04 through blockade of interleukin 1 signaling as well as ADCC. Apparently, almost 70% of PDAC patients and 80% of NSCLC patients overexpress IL1RAP on cancer cells, while in these diseases every patient has cells containing IL1RAP in the tumor microenvironment.

Source Credits: https://cantargia.com/en/press-releases/cantargia-announce-full-recruitment-of-can04-monotherapy-arm-in-ongoing-phase-iia-clinical-trial

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Nuclear Battery Market a Comprehensive Analysis Competitive Market Share & Forecast
Nuclear Battery Market a Comprehensive Analysis Competitive Market Share & Forecast
By Mateen Dalal

Nuclear Battery Market size will witness growth on account of increasing demand for efficient power generation technologies coupled with improved operational efficiency. Ability of these batteries to generate power in diverse voltage levels based on ...

MediciNova confirms Phase 3 trial of ibudilast in progressive MS
MediciNova confirms Phase 3 trial of ibudilast in progressive MS
By Mateen Dalal

Ibudilast could be the best-in-disease drug for MS patients with unmet medical needs MediciNova, Inc., a biopharmaceutical company that develops novel therapeutics and is traded on Tokyo Stock Exchange’s JASDAQ Market and on NASDAQ Global Mark...

CMIC becomes Align Clinical CRO member to enhance trial partnerships
CMIC becomes Align Clinical CRO member to enhance trial partnerships
By Mateen Dalal

The teaming up of CMIC with other companies will improve the collaboration and execution of clinical studies CMIC Group, a leading Japanese Contract Research Organization (CRO) that provides complete range of pharmaceutical drug services, recently a...